[go: up one dir, main page]

PE20130377A1 - Forma cristalina (ii) de n-benzoil-estaurosporina y procedimiento para su preparacion - Google Patents

Forma cristalina (ii) de n-benzoil-estaurosporina y procedimiento para su preparacion

Info

Publication number
PE20130377A1
PE20130377A1 PE2012002519A PE2012002519A PE20130377A1 PE 20130377 A1 PE20130377 A1 PE 20130377A1 PE 2012002519 A PE2012002519 A PE 2012002519A PE 2012002519 A PE2012002519 A PE 2012002519A PE 20130377 A1 PE20130377 A1 PE 20130377A1
Authority
PE
Peru
Prior art keywords
staurosporin
benzoyl
preparation
crystalline form
procedure
Prior art date
Application number
PE2012002519A
Other languages
English (en)
Inventor
Pascale Hoehn
Bernd Koch
Michael Mutz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35501294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20130377(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20130377A1 publication Critical patent/PE20130377A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Extraction Or Liquid Replacement (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)

Abstract

SE REFIERE A LA FORMA CRISTALINA II DE N-BENZOIL-ESTAUROSPORINA QUE PRESENTA UN PATRON DE DIFRACCION DE RAYOS X CON PICOS DE DIFRACCION A ANGULOS 2-TETA DE 3.4 ± 0.2, 6.0 ± 0.2, 7.8 ± 0.2, 8.7 ± 0.2, 9.2 ± 0.2, 9.7 ± 0.2, 10.1 ± 0.2, 10.4 ± 0.2, 11.2 ± 0.2, 12.6 ± 0.2, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCESO DE PREPARACION DE DICHA FORMA CRISTALINA QUE COMPRENDE: A) PROPORCIONAR UNA SOLUCION DE N-BENZOIL-ESTAUROSPORINA EN UN SOLVENTE TAL COMO ALCOHOL BENCILICO; B) PONER EN CONTACTO LA SOLUCION CON UN SEGUNDO SOLVENTE TAL COMO ETANOL O ETANOL EN AGUA PARA FORMAR UN PRECIPITADO; Y C) AISLAR EL PRECIPITADO
PE2012002519A 2004-11-05 2005-11-04 Forma cristalina (ii) de n-benzoil-estaurosporina y procedimiento para su preparacion PE20130377A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62534304P 2004-11-05 2004-11-05
US64213105P 2005-01-07 2005-01-07

Publications (1)

Publication Number Publication Date
PE20130377A1 true PE20130377A1 (es) 2013-04-03

Family

ID=35501294

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2005001297A PE20060947A1 (es) 2004-11-05 2005-11-04 Forma cristalina (ii) de n-benzoil-estaurosporina y procedimiento para su preparacion
PE2009000199A PE20090433A1 (es) 2004-11-05 2005-11-04 Forma cristalina (ii) de n-benzoil-estaurosporina y procedimiento para su preparacion
PE2012002519A PE20130377A1 (es) 2004-11-05 2005-11-04 Forma cristalina (ii) de n-benzoil-estaurosporina y procedimiento para su preparacion

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PE2005001297A PE20060947A1 (es) 2004-11-05 2005-11-04 Forma cristalina (ii) de n-benzoil-estaurosporina y procedimiento para su preparacion
PE2009000199A PE20090433A1 (es) 2004-11-05 2005-11-04 Forma cristalina (ii) de n-benzoil-estaurosporina y procedimiento para su preparacion

Country Status (31)

Country Link
US (2) US8198435B2 (es)
EP (3) EP2955186A1 (es)
JP (4) JP5057986B2 (es)
KR (3) KR101289998B1 (es)
CN (2) CN102627658A (es)
AR (1) AR052322A1 (es)
AU (2) AU2005300693B2 (es)
BR (1) BRPI0517689A (es)
CA (1) CA2584911C (es)
CY (1) CY1113059T1 (es)
DK (1) DK1812448T3 (es)
EC (1) ECSP12007431A (es)
ES (1) ES2388142T3 (es)
GT (1) GT200500311A (es)
HK (1) HK1211587A1 (es)
HR (1) HRP20120652T1 (es)
IL (3) IL182691A (es)
JO (1) JO2897B1 (es)
MA (1) MA29033B1 (es)
MX (2) MX346525B (es)
MY (2) MY154878A (es)
NO (2) NO338960B1 (es)
NZ (3) NZ588025A (es)
PE (3) PE20060947A1 (es)
PL (1) PL1812448T3 (es)
PT (1) PT1812448E (es)
RU (2) RU2394038C2 (es)
SI (1) SI1812448T1 (es)
TN (1) TNSN07165A1 (es)
TW (4) TWI530501B (es)
WO (1) WO2006048296A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2454220C2 (ru) * 2006-08-16 2012-06-27 Новартис Аг Способ получения твердых дисперсий высококристаллических терапевтических соединений
EP2327706A1 (en) 2009-11-30 2011-06-01 Novartis AG Polymorphous forms III and IV of N-benzoyl-staurosporine
KR20160008267A (ko) 2014-07-14 2016-01-22 주식회사 윈스 네트워크 기반 영상감시체계에서의 사용자 행위 분석 시스템
EP3592749A1 (en) 2017-03-06 2020-01-15 Teva Pharmaceutical Works Ltd. Solid state forms of midostaurin
WO2019215759A1 (en) * 2018-05-09 2019-11-14 Alaparthi Lakshmi Prasad An improved process for preparation of midostaurin
IT201900004729A1 (it) 2019-03-29 2020-09-29 Procos Spa Processo per la preparazione di midostaurina ad elevato grado di purezza
WO2020261293A1 (en) * 2019-06-24 2020-12-30 Dr. Reddy's Laboratories Limited Process for preparation of midostaurin
IT201900014346A1 (it) * 2019-08-08 2021-02-08 Procos Spa Processo per la preparazione di midostaurina amorfa con un basso contenuto di solvente organico residuo
IT202000004291A1 (it) 2020-03-02 2021-09-02 Indena Spa Processo per la purificazione di alcaloidi indolo carbazolici
CN111393454A (zh) * 2020-05-07 2020-07-10 奥锐特药业(天津)有限公司 米哚妥林的新晶型及其制备方法
CN115124551B (zh) * 2021-03-24 2024-04-30 奥锐特药业(天津)有限公司 一种高纯度米哚妥林的制备方法
US20250387404A1 (en) * 2022-04-22 2025-12-25 Rutgers, The State University Of New Jersey Formulations and methods for treating epidermolysis bullosa simplex and related conditions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5373501A (en) 1976-12-11 1978-06-30 Kitasato Inst Novel antibiotics amm2282 and process for preparing same
JPS60185719A (ja) 1984-03-06 1985-09-21 Ajinomoto Co Inc 抗腫瘍剤
IL86632A0 (en) * 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5073633A (en) 1989-03-23 1991-12-17 Bristol-Myers Company BMY-41950 antitumor antibiotic
US5096330A (en) * 1990-06-21 1992-03-17 M-B-W Inc. Pitch control mechanism for a surface finishing machine
JPH05247055A (ja) * 1992-03-03 1993-09-24 Meiji Seika Kaisha Ltd スタウロスポリン誘導体及びそれを含有する抗腫瘍効果増強剤
JPH05247955A (ja) 1992-03-06 1993-09-24 Taisei Corp 擁壁の施工方法
US5344926A (en) 1992-06-22 1994-09-06 Kyowa Hakko Kogyo Co., Ltd. Process for producing staurosporine derivatives
WO1995032975A1 (en) * 1994-06-01 1995-12-07 Ciba-Geigy Ag Indolocarbazole derivatives for sensitizing multidrug-resistant cells to antitumor agents
RU2191175C2 (ru) 1995-12-11 2002-10-20 Сефалон, Инкорпорейтед Конденсированные изоиндолоны в качестве ингибиторов протеинкиназы с
CA2382931C (en) * 1999-08-30 2011-01-25 Polyphor Ag Synthesis of template-fixed .beta.-hairpin loop mimetics
EP1372611B1 (en) 2001-03-26 2006-05-17 Novartis AG Pharmaceutical composition comprising a poorly water-soluble staurosporine, a surfactant and a water-soluble polymer
KR100407758B1 (ko) 2001-08-27 2003-12-01 씨제이 주식회사 스타틴의 제조에 있어서 락톤화 방법
WO2004094645A1 (en) 2003-04-22 2004-11-04 Lonza Ag Process for the recovery of staurosporine from a fermentation broth

Also Published As

Publication number Publication date
TWI530501B (zh) 2016-04-21
TW200628474A (en) 2006-08-16
KR101333851B1 (ko) 2013-11-27
KR101265850B1 (ko) 2013-05-20
KR20070083979A (ko) 2007-08-24
AR052322A1 (es) 2007-03-14
NZ599033A (en) 2012-09-28
AU2009245817B2 (en) 2013-02-21
CN102993213A (zh) 2013-03-27
TW201247681A (en) 2012-12-01
JP2008518995A (ja) 2008-06-05
MX2007005429A (es) 2007-05-18
NO338960B1 (no) 2016-11-07
PL1812448T3 (pl) 2012-10-31
JP2017061578A (ja) 2017-03-30
RU2394038C2 (ru) 2010-07-10
DK1812448T3 (da) 2012-08-27
US20090137552A1 (en) 2009-05-28
SI1812448T1 (sl) 2012-09-28
CA2584911C (en) 2017-10-24
EP2955186A1 (en) 2015-12-16
AU2009245817A1 (en) 2009-12-24
ECSP12007431A (es) 2012-06-29
US8710216B2 (en) 2014-04-29
KR101289998B1 (ko) 2013-07-30
HRP20120652T1 (hr) 2012-09-30
MX346525B (es) 2017-03-23
HK1108881A1 (en) 2008-05-23
TWI433852B (zh) 2014-04-11
ES2388142T3 (es) 2012-10-09
IL207702A (en) 2016-09-29
TNSN07165A1 (en) 2008-11-21
NZ554653A (en) 2010-10-29
NO20161152A1 (no) 2007-05-30
TWI455941B (zh) 2014-10-11
CY1113059T1 (el) 2016-04-13
KR20120101600A (ko) 2012-09-13
MY147404A (en) 2012-11-30
EP1812448B1 (en) 2012-05-23
JO2897B1 (en) 2015-09-15
RU2467012C2 (ru) 2012-11-20
EP2272850A3 (en) 2011-09-21
JP2012149099A (ja) 2012-08-09
JP5057986B2 (ja) 2012-10-24
RU2009137788A (ru) 2011-04-20
TW201446773A (zh) 2014-12-16
US8198435B2 (en) 2012-06-12
KR20120101601A (ko) 2012-09-13
PE20090433A1 (es) 2009-05-05
AU2005300693B2 (en) 2010-08-19
MY154878A (en) 2015-08-14
CN102627658A (zh) 2012-08-08
NO20072290L (no) 2007-05-30
MA29033B1 (fr) 2007-11-01
BRPI0517689A (pt) 2008-10-14
EP1812448A1 (en) 2007-08-01
TW201247680A (en) 2012-12-01
IL217571A (en) 2017-07-31
AU2005300693A1 (en) 2006-05-11
JP5701246B2 (ja) 2015-04-15
WO2006048296A1 (en) 2006-05-11
IL207702A0 (en) 2010-12-30
PT1812448E (pt) 2012-08-24
IL182691A (en) 2013-02-28
HK1211587A1 (en) 2016-05-27
IL182691A0 (en) 2007-09-20
EP2272850B1 (en) 2017-05-10
NZ588025A (en) 2012-04-27
PE20060947A1 (es) 2006-10-30
CA2584911A1 (en) 2006-05-11
EP2272850A2 (en) 2011-01-12
NO340404B1 (no) 2017-04-18
RU2007120695A (ru) 2008-12-10
TWI530500B (zh) 2016-04-21
JP2015063569A (ja) 2015-04-09
US20120322789A1 (en) 2012-12-20
GT200500311A (es) 2006-05-22

Similar Documents

Publication Publication Date Title
ES2483725T3 (es) Composición básica cosmética y su uso
ES2620442T3 (es) Uso de derivados de tetraquis(N-alquilpiridinio)-porfirina para la destrucción de microbios o la prevención de su crecimiento
ES2502472T3 (es) Composición adhesiva para su uso en un inmunosensor
PE20130377A1 (es) Forma cristalina (ii) de n-benzoil-estaurosporina y procedimiento para su preparacion
UY27720A1 (es) Aroilpiridinonas monocíclicas,
CL2010000516A1 (es) Composicion fungicida sin solvente que comprende estrobirulina insoluble en agua dispersado a traves del material portador en forma nano-dispersa teniendo un diametro pico de la forma nano-dispersa menor a 1000 nm; proceso para preparar dicha composicion; uso de dicha composicion para tratar una infestacion (divisional de la sol. 2030-07).
DK1959992T3 (da) Immunogen sammensætning indeholdende en adjuvans.
ECSP077999A (es) Formulaciones de una sal de bupropion de liberación modificada
IT1392903B1 (it) Composizione comprendente un'associazione di principi attivi per uso nel trattamento topico della calvizie
AR056055A1 (es) Complejos cristalinos e hidratos de 1-cloro-4-(beta-d-glucopiranos-1-il)-2-(4-etinil-bencil)-benceno
BRPI0719849A2 (pt) Método de imunização contra os quatro sorotipos da dengue
LU92550I2 (fr) Lurasidone, facultativement sous forme de sa base libre ou de ses sels pharmaceutiquement acceptables
CL2007001918A1 (es) Compuestos derivados heteroarilos sustituidos; metodo para la preparacion de los compuestos; composicion farmaceutica; y uso para el tratamiento del dolor, depresion, enfermedad de alzheimer e hipertension entre otras.
BRPI0510231A (pt) composto, polimorfo cristalino, cossolvato em metanol e água, cossolvato em metanol-água, cossolvato em etanol-água, composição farmacêutica, método para administrar um agente ativo, método para preparar a forma i do snac, método para preparar a forma ii de snac, método para preparar a forma iii de snac, método para preparar a forma iv de snac, método para preparar a forma v de snac, método para preparar a forma vi de snac, composição farmacêutica e método para preparar snac amorfo
ECSP10010303A (es) (dihidro)pirrolo[2,1-a]isoquinolinas
UY31758A (es) Forma cristalina anhidra de maleato de orvepitant
ES2581331T3 (es) Inhibidor de la progresión de una enfermedad atribuida a una acumulación anormal de grasa hepática
ECSP099506A (es) Derivados de 2-quinolinona y 2 quinoxalinona y su utilización como agentes anti bacterianos
WO2006081008A3 (en) Nucleic acids for apoptosis of cancer cells
ECSP099596A (es) Composición farmacéutica que contiene una combinación de tramadol y ketoprofeno
AR042712A1 (es) Uso de inhibidores de quinurenina 3- hidroxilasa para el tratamiento de la diabetes por incremento de la cantidad de celulas de los islotes de langerhans
AR055761A1 (es) Procedimiento para preparar especies de aluminio
ECSP088647A (es) Nueva sal de citrato de un derivado de indol y su uso farmacéutico
AR062204A1 (es) Formas solidas de (3'-clorobifeni-4-il)(1-pirimidin-2-il)piperidin-4-il)metanona, un metodo de preparacion, una dosificacion farmaceutica que la comprende y su uso en eltratamiento de trastornos cognitivos y de la enfermedad de alzheimer.
WO2007121054A3 (en) Nucleic acids for apoptosis of cancer cells

Legal Events

Date Code Title Description
FC Refusal